Core Insights - The Fundsmith Equity Fund reported a total return of +0.8% for 2025, underperforming the MSCI World Index which rose by +12.8% [4][7]. - Since inception on November 1, 2010, the Fund has outperformed the Index by 1.7% per annum with a Sortino Ratio of 0.75, indicating less downside volatility compared to the Index [7][8]. - The Fund is ranked as the third best performer in the Investment Association Global sector of 155 funds since inception, with a return 322 percentage points above the sector average [8]. Performance Analysis - The Fund's performance in 2025 was impacted by three main issues: index concentration, the growth of assets in index funds, and dollar weakness [9][10][36]. - The top ten stocks in the S&P 500 accounted for 39% of its value and contributed 50% of its total return in USD by the end of 2025, highlighting significant market concentration [13][10]. - The rise of index funds has led to a momentum strategy that disproportionately benefits large-cap stocks, making it challenging for active funds to compete without holding these stocks [17][20]. Market Dynamics - The US dollar weakened against the pound from approximately $1.25/GBP to $1.35/GBP during 2025, affecting the GBP value of the Fund as most companies are US-listed [36][40]. - The price of gold reached a 50-year high of $4,319 per ounce, reflecting concerns about dollar strength and market conditions [39]. Portfolio Composition - The Fund's portfolio turnover was low at 12.7%, with a total cost of investment (TCI) of 1.06%, indicating a focus on minimizing trading costs [70][72]. - The weighted average free cash flow yield of the portfolio increased from 3.1% to 3.7% during 2025, suggesting improved valuation relative to the S&P 500 [68][69]. Stock Contributions - The top five detractors from the Fund's performance included Novo Nordisk, Automatic Data Processing, Church & Dwight, Coloplast, and Fortinet, with Novo Nordisk facing significant challenges in its market [45][46]. - Conversely, the top contributors were Alphabet, IDEXX, Philip Morris, Meta Platforms, and Microsoft, with Alphabet making its first appearance among the top contributors [51][52]. Investment Strategy - The Fund maintains a strategy focused on investing in high-quality companies with predictable growth and adequate returns on capital, avoiding momentum-driven investments [41][42]. - The Fund's management emphasizes the importance of understanding the underlying business performance and maintaining a long-term perspective on investments [60][79].

Core Insights - EssilorLuxottica achieved its best quarterly performance ever, with consolidated revenue reaching Euro 6,867 million in Q3 2025, marking an 11.7% year-on-year increase at constant exchange rates compared to Q3 2024 [1][6] Financial Performance - Revenue increased by 11.7% in Q3 2025 at constant exchange rates and 6.7% at current exchange rates compared to the previous year [1][6] - For the first nine months of 2025, revenue grew by 8.8% [6] Market Contributions - Strong contributions from EMEA and North America were highlighted, with both regions experiencing double-digit growth in both PS and DTC channels [2][6] - The wearables segment significantly boosted revenue, supported by a robust pipeline of product innovation [6] Product Innovations - The company unveiled its most advanced portfolio of AI glasses, including the next generations of Ray-Ban Meta and Oakley Meta glasses, as well as Meta Ray-Ban Display [3] - Stellest lenses, aimed at myopia management, received FDA market authorization, marking a new category in the U.S. [3][6] Strategic Developments - The acquisition of RetinAI was announced, and Optegra was closed, set to be consolidated from October 1 [6] - The company aims to drive lasting transformation by integrating innovation, science, and human potential [4]

Core Insights - EssilorLuxottica achieved its best quarterly performance ever, with consolidated revenue reaching Euro 6,867 million in Q3 2025, marking an 11.7% year-on-year increase at constant exchange rates [1][6] - The growth was significantly driven by strong contributions from the EMEA and North America regions, particularly in wearables, vision care, and sunglasses [2][6] Revenue Performance - Revenue increased by 11.7% in Q3 2025 at constant exchange rates, and by 8.8% over the first nine months of the year [6] - Vision care and sunglasses segments grew by 5% at constant exchange rates [6] Product Innovation and Market Expansion - The company launched its most advanced portfolio of AI glasses, including the next generations of Ray-Ban Meta and Oakley Meta glasses, enhancing its position in wearable technology [3] - Stellest lenses received FDA market authorization, marking a significant advancement in myopia management in the U.S. [6] Strategic Acquisitions - The acquisition of RetinAI was announced, and Optegra has been closed, with consolidation effective from October 1 [6]